Novel concept of “sequential particle radiotherapy” with atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus-Reference-Cited by-同舟云学术

Novel concept of “sequential particle radiotherapy” with atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus

Published:2024-03-04 Issue:8 Volume:54 Page:972-976
ISSN:0941-1291
Container-title:Surgery Today
language:en
Short-container-title:Surg Today

Author:

Komatsu Shohei,Terashima Kazuki,Ishihara Nobuaki,Matsuo Yoshiro,Kido Masahiro,Yanagimoto Hiroaki,Toyama Hirochika,Tokumaru Sunao,Okimoto Tomoaki,Fukumoto Takumi

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00595-024-02805-1.pdf

Reference11 articles.

1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

2. Kudo M. Atezolizumab plus Bevacizumab followed by Curative Conversion (ABC Conversion) in patients with Unresectable TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 2022;11:399–406.

3. Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Sasaki R, et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer. 2011;117:4890–904.

4. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65:938–43.

5. Breder V, Vogel A, Merle P, Finn RS, Galle PR, Zhu AX, et al. IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study. J Clin Oncol. 2021;39(15 suppl):4073.